C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Rating of “Moderate Buy” by Brokerages

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been given an average rating of “Moderate Buy” by the six research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $7.75.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a report on Friday, July 17th.

Institutional Investors Weigh In On C4 Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CCCC. SummitTX Capital L.P. purchased a new position in C4 Therapeutics in the first quarter worth $28,000. CTC Alternative Strategies Ltd. purchased a new stake in shares of C4 Therapeutics during the 1st quarter valued at $28,000. Zacks Investment Management purchased a new stake in shares of C4 Therapeutics during the 3rd quarter valued at $29,000. California State Teachers Retirement System acquired a new stake in shares of C4 Therapeutics in the 2nd quarter worth $30,000. Finally, Delta Investment Management LLC acquired a new stake in shares of C4 Therapeutics in the 4th quarter worth $38,000. Hedge funds and other institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Price Performance

Shares of NASDAQ CCCC opened at $4.24 on Thursday. C4 Therapeutics has a 1-year low of $1.69 and a 1-year high of $5.17. The business has a fifty day moving average price of $3.97 and a 200 day moving average price of $3.32. The stock has a market capitalization of $521.65 million, a P/E ratio of -4.24 and a beta of 2.91.

C4 Therapeutics (NASDAQ:CCCC) last posted its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $6.64 million for the quarter, compared to analyst estimates of $4.00 million. C4 Therapeutics had a negative return on equity of 45.45% and a negative net margin of 289.44%. As a group, equities research analysts anticipate that C4 Therapeutics will post -0.85 earnings per share for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.